ReviewActa pharmaceutica Sinica. B2024
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.
Review in Acta pharmaceutica Sinica. B, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed.
- Revisiting tumor immunogenicity through the lens of mutant p53: Implications for cancer immunotherapy.Apoptosis : an international journal on programmed cell death · 2026Review
- Covalent Organic Framework Bispecific Nanosystem for the Combined Treatment of Acute Myeloid Leukemia.Materials (Basel, Switzerland) · 2026Article
- IL-18 derived from microwave-ablated osteosarcoma facilitates antitumor response.Journal for immunotherapy of cancer · 2026Article
- Genetic architecture of multiple myeloma: From somatic alterations to germline susceptibility and clinical implications.Translational oncology · 2026Review
- From T cell engagers to next-generation immune cell engagers for cancer immunotherapy.Antibody therapeutics · 2026Review
- Parallel Sequencing of the Two Arms on a Bispecific Antibody by Electron Capture Dissociation on a timsOmni Platform Reveals Several By-products in the Controlled Fab-arm Exchange Process.Analytical chemistry · 2026Article
- Oxygen-carrying nanovaccine potentiates cancer immunotherapy for heterogeneous solid tumors.Materials today. Bio · 2026Article
- Oncolytic adenoviruses encoding bispecific T cell engagers or a novel trispecific T cell engager for dual-targeting of c-MET and EGFR.Molecular therapy. Oncology · 2026Article
- Efficacy and safety of approved cellular therapies and bispecific antibodies in solid tumors: the current state.Discover oncology · 2026Review
- Harnessing a bispecific αGD2 × αCD3 protein engager to target GD2-overexpressing lung tumors.Scientific reports · 2026Article
- First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?Drugs · 2026Review
- Oncolytic Viruses in Cancer Immunotherapy: From Molecular Engineering to Clinical Translation.Cells · 2026Review
- The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma.Clinical and experimental medicine · 2026Review
- Immunotherapy in clear cell renal cell carcinoma: current Status, novel Strategies, and future perspectives.Clinical and experimental medicine · 2026Review
- T-cell engagers in cancer immunotherapy: mechanisms, challenges, and future perspectives.Frontiers in immunology · 2026Review
- Reconceptualizing glioblastoma immunotherapy: a four-pillar framework to overcome multidimensional resistance.Frontiers in medicine · 2026Review
- A New Paradigm of Bispecific Antibodies in Clinical Management of Gastrointestinal Cancers.Oncology research · 2026Review
- CLDN18.2-Directed Therapeutics in Gastric and Gastroesophageal Junction Adenocarcinoma: Biomarker Assessment, Expression Dynamics, and Treatment Sequencing.Cancer management and research · 2026Review
- T-cell redirecting therapies in lung cancer - a comprehensive analysis of clinical trials.Frontiers in immunology · 2026Review
- Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy.Molecular cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
T cell-redirecting bispecific antibodies are specifically designed to bind to tumor-associated antigens, thereby engaging with CD3 on the T cell receptor. This linkage between tumor cells and T cells actively triggers T cell activation and initiates targeted killing of the identified tumor cells. These antibodies have emerged as one of the most promising avenues within tumor immunotherapy. However, despite success in treating hematological malignancies, significant advancements in solid tumors have yet to be explored. In this review, we aim to address the critical challenges associated with T cell-redirecting bispecific antibodies and explore novel strategies to overcome these obstacles, with the ultimate goal of expanding the application of this therapy to include solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.